Financials data is unavailable for this security.
View more
Year on year Shanghai Haixin Group Co Ltd had little change in net income (from 164.06m to 166.03m) despite revenues that fell -17.88% from 1.44bn to 1.18bn.
| Gross margin | 49.64% |
|---|---|
| Net profit margin | 20.39% |
| Operating margin | 21.82% |
| Return on assets | 3.93% |
|---|---|
| Return on equity | 4.22% |
| Return on investment | 4.50% |
More ▼
Cash flow in CNYView more
In 2023, Shanghai Haixin Group Co Ltd increased its cash reserves by 15.55%, or 65.36m. Cash Flow from Investing totalled 158.78m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 35.88m for operations while cash used for financing totalled 57.82m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.22 |
|---|---|
| Tangible book value per share | 3.21 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.61 |
|---|---|
| Quick ratio | 2.44 |
| Total debt/total equity | 0.0215 |
|---|---|
| Total debt/total capital | 0.0202 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 44.44% and 1.21%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.57% |
|---|---|
| Div growth rate (5 year) | 13.18% |
| Payout ratio (TTM) | 47.23% |
| EPS growth(5 years) | 4.20 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 18.26 |
More ▼
